2021
Characterizing COVID-19 clinical phenotypes and associated comorbidities and complication profiles
Lusczek ER, Ingraham NE, Karam BS, Proper J, Siegel L, Helgeson ES, Lotfi-Emran S, Zolfaghari EJ, Jones E, Usher MG, Chipman JG, Dudley RA, Benson B, Melton GB, Charles A, Lupei MI, Tignanelli CJ. Characterizing COVID-19 clinical phenotypes and associated comorbidities and complication profiles. PLOS ONE 2021, 16: e0248956. PMID: 33788884, PMCID: PMC8011766, DOI: 10.1371/journal.pone.0248956.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsClinical phenotypePhenotype IIIClinical outcomesCOVID-19 clinical phenotypesHours of admissionPhenotype IHazard of deathCoronavirus disease 2019Specific clinical phenotypesCOVID-19 phenotypesHospital complicationsRespiratory comorbiditiesPatient comorbiditiesDifferent comorbiditiesComplication profilePatient populationAdmission characteristicsMultivariable modelRetrospective analysisDisease 2019ComorbiditiesTrial designPatientsClinical practice
2020
mTOR inhibition in COVID‐19: A commentary and review of efficacy in RNA viruses
Karam BS, Morris RS, Bramante CT, Puskarich M, Zolfaghari EJ, Lotfi‐Emran S, Ingraham NE, Charles A, Odde DJ, Tignanelli CJ. mTOR inhibition in COVID‐19: A commentary and review of efficacy in RNA viruses. Journal Of Medical Virology 2020, 93: 1843-1846. PMID: 33314219, PMCID: PMC8159020, DOI: 10.1002/jmv.26728.Peer-Reviewed Original ResearchConceptsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionCoronavirus 2 infectionReview of efficacyCoronavirus disease 2019Modulation of mTORSARS-CoV-2RNA virusesDisease 2019Recent evidence pointsMTOR inhibitorsViral infectionMTOR inhibitionMTOR pathwayMammalian targetRapamycin (mTOR) pathwayNumerous RNA virusesVirus growthCOVID-19MTOR resultsInfectionCurrent literatureHighlight evidenceEvidence points